Date: 2016-10-13
Type of information: Nomination
Compound:
Company: Kite Pharma (USA - CA)
Therapeutic area: Cancer - Oncology - Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On October 13, 2016, Kite Pharma announced the appointment of Chris Nowers as its Head of Europe . Chris Nowers will be based in London .He will oversee European commercial operations to build awareness in the region of Kite's growing pipeline portfolio of chimeric antigen receptor (CAR) and T-cell receptor (TCR) therapy product candidates and prepare for the potential launch of the company's lead product candidate, KTE-C19. Prior to joining Kite, Nowers held senior commercial leadership positions at BMS, including Head of Immuno-oncology and Hematology in France , where he led the successful launch of Opdivo® (nivolumab), and as Vice President of Global Commercialization for Yervoy® (ipilimumab), where he led the global commercial launch. Previously, Chris Nowers was Vice President of Sales and Marketing at Genomic Health, and Chief Executive Officer of Avantogen Oncology, a company developing early-stage cancer therapeutics. Nowers also served 11 years at Amgen in a variety of commercial leadership roles, including Global Commercial Leader for Neurology and European Director for Oncology and Hematology.
Financial terms:
Latest news:
